Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Kyverna Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cell therapies for patients with severe autoimmune diseases. The company operates within the biotechnology and biopharmaceutical industries, with a specific emphasis on engineering chimeric antigen receptor T-cell (CAR T) therapies designed to reset the immune system rather than broadly suppress it. Kyverna’s core strategy is to adapt advances from oncology CAR T therapies to address the underlying drivers of autoimmunity.
The company’s primary revenue drivers are currently research and development activities, as it does not yet have approved commercial products. Kyverna targets patients with refractory or severe autoimmune conditions, initially focusing on diseases with high unmet medical need such as lupus nephritis and other antibody-mediated disorders. Its differentiation lies in applying fully human, CD19-directed CAR T-cell technology with the goal of achieving durable remissions. Kyverna was founded in 2018 and has since evolved from a privately funded research-focused company into a publicly traded clinical-stage biotechnology firm following its initial public offering in 2024.
Business Operations
Kyverna’s operations are organized around the research, development, and clinical advancement of its CAR T-cell therapy programs. Its lead product candidate, KYV-101, is a fully human anti-CD19 CAR T therapy being evaluated across multiple autoimmune indications. The company generates no commercial revenue to date and primarily funds operations through equity financing and cash reserves, with expenditures concentrated on clinical trials, manufacturing scale-up, and regulatory activities.
Operationally, Kyverna conducts its development activities through a combination of internal capabilities and external partnerships. Manufacturing of CAR T therapies relies on specialized cell processing technologies, including autologous T-cell collection, genetic modification, and reinfusion. The company maintains clinical trial operations in collaboration with academic medical centers and clinical research organizations. Kyverna is the parent company of Kyverna Therapeutics GmbH, which supports its European research and clinical footprint.
Strategic Position & Investments
Kyverna’s strategic direction centers on establishing CAR T therapy as a transformative treatment paradigm in autoimmune disease. Near-term growth initiatives focus on advancing KYV-101 through mid- to late-stage clinical trials across multiple indications, while expanding its pipeline into additional autoimmune and inflammatory diseases. The company is also investing in manufacturing optimization to improve scalability, consistency, and cost efficiency of autologous cell therapies.
The company’s portfolio strategy includes maintaining a focused pipeline rather than broad diversification, prioritizing depth in immune-mediated diseases. Kyverna has not announced large-scale acquisitions since becoming public, but it continues to invest heavily in internal research and development and selectively licenses technologies that enhance its CAR T platform. Its work positions the company at the intersection of cell therapy, immunology, and precision medicine.
Geographic Footprint
Kyverna Therapeutics is headquartered in the United States, with its principal executive offices in California. Its operational presence extends to Europe through its German subsidiary, supporting clinical development and regulatory engagement in European markets. Clinical trials are conducted across multiple sites in North America and Europe, reflecting the company’s international development strategy.
While Kyverna does not yet have commercial operations, its global footprint is designed to support future regulatory approvals and commercialization in major pharmaceutical markets. The company’s international activities are primarily research- and development-oriented, with a focus on regions that have established infrastructure for advanced cell therapy trials.
Leadership & Governance
Kyverna is led by an executive team with experience in biotechnology, immunology, and clinical drug development. The leadership emphasizes scientific rigor, patient-centric development, and disciplined execution of clinical programs aimed at high-impact autoimmune indications.
- Peter Maag – President and Chief Executive Officer
- Eric Maier – Chief Financial Officer
- Paul Grint, M.D. – Chief Medical Officer
- Andrew Adams, Ph.D. – Chief Scientific Officer
- Michael C. Erickson – Chief Legal Officer and Secretary
The company is governed by a board of directors with backgrounds in biopharmaceutical development, finance, and corporate governance, supporting Kyverna’s long-term strategy of advancing innovative cell therapies toward regulatory approval and commercialization.